Sezer, A.Kılıçkap, SaadettinGümüş, MBondarenko, IgorÖzgüroğlu, MustafaGogishvili, MirandaHe, X.Gullo, GuiseppeRietschel, PetraQuek, Ruben2022-12-212022-12-212022Sezer, A., Kilickap, S., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., ... & Quek, R. (2022). 1183P Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups. Annals of Oncology, 33, S1089.0923-75341569-8041http://dx.doi.org/10.1016/j.annonc.2022.07.1306https://hdl.handle.net/20.500.12713/3758Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroupseninfo:eu-repo/semantics/openAccessOther337S1089S1089WOS:000866211601445Q110.1016/j.annonc.2022.07.1306